These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19416133)

  • 21. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness and safety of lansoprazole in the treatment of peptic ulcer].
    Ramón Nogueira J; Esquivel Ayanegui F; Esquivel Rodríguez F; Sáenz V; Santoyo R
    Rev Gastroenterol Mex; 1996; 61(4):314-9. PubMed ID: 9072782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
    Kovacs TO; Freston JW; Haber MM; Hunt B; Atkinson S; Peura DA
    Dig Dis Sci; 2009 Aug; 54(8):1693-701. PubMed ID: 19267194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
    Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W
    Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
    Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
    BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
    Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
    Peura DA; Freston JW; Haber MM; Kovacs TO; Hunt B; Atkinson S
    Dig Dis Sci; 2009 May; 54(5):955-63. PubMed ID: 18726153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.
    Maton PN; Vakil NB; Levine JG; Hwang C; Skammer W; Lundborg P;
    Drug Saf; 2001; 24(8):625-35. PubMed ID: 11480494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
    Chen S; Liu D; Chen H; Liao A; Li F; Liu C; Li X; Li S; Zhang Y; Wang Y; Xia M; Guo Q; Miao X; Wen Z; Xu M; Yin H; Chen H; Chen M; Xiao Y
    Aliment Pharmacol Ther; 2022 Jun; 55(12):1524-1533. PubMed ID: 35505467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
    Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
    Cho YK; Kim JH; Kim HS; Kim TO; Oh JH; Choi SC; Moon JS; Lee SK; Jung SW; Kim SS; Jung HK; Lee SP; Cheon GJ; Park MI; Jung HY; Ko KH; Sung IK; Lee SH; Lee JY; Lee ST; Rhee PL; Kim N; Hong SJ; Kim HJ; Kim GH; Lee KJ; Kim SK; Shin WG; Lee OY
    Aliment Pharmacol Ther; 2023 Jan; 57(1):72-80. PubMed ID: 36314172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linear mucosal defects: a characteristic endoscopic finding of lansoprazole-associated collagenous colitis.
    Nomura E; Kagaya H; Uchimi K; Noguchi T; Suzuki S; Suzuki M; Onodera H; Tateno H
    Endoscopy; 2010; 42 Suppl 2():E9-10. PubMed ID: 20066608
    [No Abstract]   [Full Text] [Related]  

  • 36. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature.
    Capurso G; Marignani M; Attilia F; Milione M; Colarossi C; Zampaletta C; Di Giulio E; Delle Fave G
    Dig Liver Dis; 2011 May; 43(5):380-5. PubMed ID: 21195042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lansoprazole-induced acute interstitial nephritis.
    Eken J; Phadke G; Ahmed S; Mahale A
    South Med J; 2009 Mar; 102(3):335-6. PubMed ID: 19204634
    [No Abstract]   [Full Text] [Related]  

  • 38. [Drug-induced microscopic colitis].
    Kummer O; Novakova K; Burkard T; Hammann F; Krähenbühl S; Bodmer M
    Praxis (Bern 1994); 2007 Aug; 96(35):1293-7. PubMed ID: 18293881
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety review in 10,008 users of lansoprazole in daily practice.
    Claessens AA; Heerdink ER; Van Eijk JT; Lamers CB; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2000 Sep; 9(5):383-91. PubMed ID: 19025844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer.
    Paz MFCJ; de Alencar MVOB; de Lima RMP; Sobral ALP; do Nascimento GTM; Dos Reis CA; Coêlho MDPSS; do Nascimento MLLB; Gomes Júnior AL; Machado KDC; de Menezes APM; de Lima RMT; de Oliveira Filho JWG; Dias ACS; Dos Reis AC; da Mata AMOF; Machado SA; Sousa CDC; da Silva FCC; Islam MT; de Castro E Sousa JM; Melo Cavalcante AAC
    Oxid Med Cell Longev; 2020; 2020():3457890. PubMed ID: 32308801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.